Can adding interferon boost immunotherapy against liver cancer?
NCT ID NCT07769827
First seen Aug 18, 2026 · Last updated Aug 18, 2026
Summary
This study tests whether adding pegylated interferon alpha-2b to standard targeted immunotherapy can help people with advanced liver cancer caused by hepatitis B. The trial enrolls adults with unresectable, intermediate-to-advanced disease who are already on antiviral therapy. Participants receive the combination in cycles until the cancer progresses or side effects become unacceptable. The goal is to see if this approach improves progression-free survival and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pegylated interferon alpha-2b (PegIntron®) combined with targeted immunotherapy (PD-1 inhibitors and targeted therapy)
- What this could lead to
- If effective, this combination could extend survival and delay cancer progression in people with advanced HBV-related liver cancer who have limited options.
- What could go wrong
- This is a small, early real-world study, so results may not be conclusive. Adding interferon can cause flu-like symptoms, fatigue, and other side effects that may limit tolerability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV-HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Jinling Hospital, Nanjing University Medical School
RECRUITINGNanjing, Jiangsu, China